Symbiq Infusion System by Hospira: FDA Safety Communication

[Posted 07/31/2015] AUDIENCE: Risk Manager, Oncology, Nursing ISSUE: The FDA, the U.S. Department of Homeland Security’s Industrial Control Systems Cyber Emergency Response Team (ICS-CERT), and Hospira are aware of cybersecurity vulnerabilities associated with the Symbiq Infusion System. FDA strongly encourages health care facilities transition to alternative infusion systems, and discontinue use of these pumps. Hospira…

Sterile Human and Veterinary Compounded Drugs by Moses Lake Professional Pharmacy: Recall

[Posted 07/24/2015]  AUDIENCE: Health Professional, Pharmacy, Veterinary, Patient ISSUE: Moses Lake Professional Pharmacy is voluntarily recalling human and veterinary sterile compounded drugs which are unexpired to the consumer level due to lack of sterility assurance.The company has not received any reports of product contamination or adverse events to date, and is issuing this voluntary recall…

Proglycem (diazoxide): Drug Safety Communication

[Posted 07/16/2015] AUDIENCE: Pulmonology, Pediatrics, Nursing, Critical Care Medicine ISSUE:  FDA is warning that a serious lung condition called pulmonary hypertension, which is high pressure in the blood vessels leading to the lungs, has been reported in infants and newborns treated with Proglycem (diazoxide) for low blood sugar. In all cases, the pulmonary hypertension resolved…